Circulating Tumor Cell News and Research

RSS

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research taking place in Orlando, Florida April 2-6, 2011.

1 Apr 2011

Engineers create new microfluidic device that can detect cancer cells, HIV

A Harvard bioengineer and an MIT aeronautical engineer have created a new device that can detect single cancer cells in a blood sample, potentially allowing doctors to quickly determine whether cancer has spread from its original site.

30 Mar 2011

New analytic method suggests tumors grow in punctuated, staccato-like bursts

A new method of analyzing cancerous tumors developed by scientists at Cold Spring Harbor Laboratory suggests that tumors may not evolve gradually, but rather in punctuated or staccato-like bursts.

14 Mar 2011

Scientists develop innovative device to efficiently identify CTCs in blood

Circulating tumor cells, which play a crucial role in cancer metastasis, have been known to science for more than 100 years, and researchers have long endeavored to track and capture them.

8 Mar 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

Tiny gold particles can help doctors detect CTCs in blood of patients with head, neck cancer

Tiny gold particles can help doctors detect tumor cells circulating in the blood of patients with head and neck cancer, researchers at Emory and Georgia Tech have found.

14 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Massachusetts General Hospital (MGH) has entered into a collaborative agreement with Veridex LLC to establish a center of excellence in research on circulating tumor cell (CTC) technologies. The overall goal of the agreement is to develop and commercialize novel technologies for capturing and characterizing CTCs, solid tumor cells found at extremely low levels in the bloodstream, which may offer a key to noninvasive characterization of cancer and potentially to early detection.

4 Jan 2011

Presence of CTCs may predict disease recurrence in patients with neck and head cancer

A new study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival.

21 Dec 2010

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.

13 Dec 2010

CTCs in metastatic breast cancer patients linked to cancer recurrence, poor survival rates

Metastatic breast cancer patients who had circulating tumor cells (CTCs) in their blood before or after high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation had poor outcomes, according to researchers from the University of Texas MD Anderson Cancer Center.

13 Dec 2010

High CTC level found to be early marker of poor outcome in metastatic breast cancer

A high level of circulating tumor cells (CTCs) - cells that have detached from a tumor and are circulating in the body through the blood - are an independent prognostic marker in metastatic breast cancer as first-line therapy.

13 Dec 2010

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Idera Pharmaceuticals, Inc. today presented data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments, rituximab or bortezomib, significantly increased antitumor activity in several preclinical lymphoma models. The presentation, entitled "Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies," was made at the 52nd Annual Meeting of the American Society for Hematology in Orlando, Florida by Idera scientists.

7 Dec 2010

Noncancerous cells from primary site appear to facilitate tumor growth: Study

The process of metastasis requires that cancer cells traveling from a primary tumor find a hospitable environment in which to implant themselves and grow. A new study from Massachusetts General Hospital (MGH) Cancer Center researchers finds that circulating tumor cells prepare this environment by bringing along from their original site noncancerous cells that support tumor growth. The report has been published online in PNAS Early Edition.

1 Dec 2010

33rd CTRC-AACR Symposium to feature breast cancer research

The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year's symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

12 Nov 2010

NaturalNano's HNT can improve separation of CTCs from blood

NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.

12 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

Redesigned version of CTC-Chip effective in capturing rare circulating tumor cells

A redesigned version of the CTC-Chip a microchip-based device for capturing rare circulating tumor cells (CTCs) appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells.

13 Oct 2010

Circulating Tumor Cell News and Research

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Engineers create new microfluidic device that can detect cancer cells, HIV

New analytic method suggests tumors grow in punctuated, staccato-like bursts

Scientists develop innovative device to efficiently identify CTCs in blood

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Tiny gold particles can help doctors detect CTCs in blood of patients with head, neck cancer

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

LabCorp to market On-Q-ity's circulating tumor cell platform

Single cancer cell could be detected in future using new test

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Presence of CTCs may predict disease recurrence in patients with neck and head cancer

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

CTCs in metastatic breast cancer patients linked to cancer recurrence, poor survival rates

High CTC level found to be early marker of poor outcome in metastatic breast cancer

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Noncancerous cells from primary site appear to facilitate tumor growth: Study

33rd CTRC-AACR Symposium to feature breast cancer research

NaturalNano's HNT can improve separation of CTCs from blood

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Redesigned version of CTC-Chip effective in capturing rare circulating tumor cells

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics